logo
Ottawa-based organization's pre-budget submission takes aim at women's health funding

Ottawa-based organization's pre-budget submission takes aim at women's health funding

Yahoo5 days ago
An Ottawa-based organization is urging the federal government to allocate millions of dollars in Budget 2025 to address gaps and misinformation in women's health, saying the money will advance women's health care across the country.
The Society of Obstetricians and Gynaecologists of Canada (SOGC) is a national organization dedicated to advancing women's health and advocating for better health-care policies across the country.
In its pre-budget submission, the organization outlined five key recommendations for government officials to consider while drafting Budget 2025, which is expected to drop in the fall.
One of those recommendations is a $20 million investment to close data gaps in women's health by creating a National Women's Health Data Dashboard and improve data collection strategies.
The SOGC says the dashboard, which should be a standardized and disaggregated database, will provide meaningful insights into key women's health indicators. This includes data on maternal mortality and morbidity, stillbirth and perinatal loss, menopause and endometriosis.
This will help patients make informed decisions about their health and also allow health-care providers to provide more responsive, equitable and cost-effective care, the SOGC added.
The organization also said the move will also have economic benefits because incomplete data leads to lost productivity and greater costs to the health-care system. Patients often have to foot hefty bills from unnecessary health-care costs.
Currently, provinces and territories are responsible for collecting this data and practices may vary widely.
'The federal government must take a leadership role in co-ordinating and standardizing this data collection, as approaches to health data collection across provinces and territories vary widely. Only national leadership can ensure consistency, comparability and the quality needed to build a reliable, actionable and nationally-focused database and dashboard,' the pre-budget submission read.
'Without co-ordinated, federally driven health data infrastructure, Canada will continue to miss emerging health trends, fall short in reducing system costs and fail to support women whose pain and illness limit their ability to fully participate in the economy.'
The recommendation comes after Prime Minister Mark Carney made several promises to protect women's rights in Canada throughout his federal election campaign earlier this year.
This includes investments to increase data collection to 'help address women's health gaps in Canada,' as well as investments into under-researched areas like postpartum maternal health.
But the platform did not provide specific details about how much money will be allocated to this initiative.
'Under a Liberal government, women's rights in Canada will never be compromised. We will protect these rights, and fight for true equity for women — in health, in the workplace, and in their access to fundamental rights,' the 2025 Liberal Party federal election platform reads.
The Liberal Party of Canada also pledged to invest into women's sexual and reproductive health care and health research, including those who identify as 2SLGBTQI+.
Women's health still under-researched, underfunded
Advocates have been talking about the lack of awareness and knowledge around women's health for years, saying it is a result of historical gender inequality in the research process.
Research published in April this year found that the percentage of research abstracts mentioning sex, gender and LGBTQ2S+ populations doubled or quadrupled from 2020 to 2023 but remained at under 10 per cent of overall funded research.
The number of female-specific research didn't change much between 2020 to 2023 — female-specific research only made up about seven per cent of all research between 2020 to 2023. A large bulk of that research focused on cancers (breast and gynecologic) or pregnancy.
This is despite the Health Portfolio Sex- and Gender-Based Analysis Plus Policy, which mandates for integrated sex and gender-based analyses in Canada. That policy came into effect in 2009 and aimed to promote diversity, equity and inclusion in health research.
'Mandates are not affecting the percentage of funding for women's health grants. More efforts and support beyond sex and gender mandates are needed to increase funding for and to diversify female-specific research beyond pregnancy and cancer. Research devoted to women's health factors is key to achieving personalized medicine and improved health outcomes for everyone,' the researchers wrote.
The lack of funded research into women's health also means many Canadians are misinformed and susceptible to disinformation.
A 2024 Abacus report commissioned by the Canadian Medical Association (CMA) showed that a majority of Canadians now seek news and information online over TV or radio. Female respondents were more likely than men to use social media and online platforms to find information on specific health conditions, symptoms or treatment options.
'Given the complexity of women's health issues, which can range from endometriosis, polycystic ovarian syndrome (PCOS), menopause and more, the quest for information is real. Women are more likely to experience dismissal or minimization of their symptoms, perpetuating stigma and shame,' the CMA said in a post published in March 2024.
'Algorithms that favour clicks and likes to the detriment of evidence-based facts make it increasingly difficult to discern health facts from fiction.'
A 2021 survey from three women's health foundations in Canada — the BC Women's Health Foundation, the Alberta Women's Health Foundation and the Women's College Hospital Foundation — found that a majority of Canadians were misinformed about women's health.
The survey suggests that 83 per cent of Canadians didn't know that 30 per cent of women suffer from periods severe enough to interfere with daily activities.
The report also said only 20 per cent of Canadians knew that heart disease kills more women than men each year.
'For so long, women's specific health needs have been largely ignored, under-researched, and underfunded. In fact, it takes 17 years for clinical research to filter down to medical practice, but women have only been included in trials for the past 20 years,' said Jennifer Bernard in 2021. Bernard is currently the president and CEO of the SickKids Foundation but was the former president and CEO of the Women's College Hospital Foundation from 2018 to 2023.
Our website is your destination for up-to-the-minute news, so make sure to bookmark our homepage and sign up for our newsletters so we can keep you informed.
Related
How to stay safe near the Ottawa River's Deschênes Rapids
Federal cuts are freezing new grads out of the public service
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Vertex Pharmaceuticals Incorporated (VRTX) Launches JOURNAVX, First Non-Opioid Acute Pain Treatment
Vertex Pharmaceuticals Incorporated (VRTX) Launches JOURNAVX, First Non-Opioid Acute Pain Treatment

Yahoo

time4 minutes ago

  • Yahoo

Vertex Pharmaceuticals Incorporated (VRTX) Launches JOURNAVX, First Non-Opioid Acute Pain Treatment

We recently compiled a list of Vertex Pharmaceuticals Incorporated stands second on our list and has recently launched the first non opioid acute pain treatment. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), a global biotech firm based in Boston, is known for developing innovative treatments for serious diseases like cystic fibrosis, sickle cell disease, and beta thalassemia. The company is recognized for its strong pipeline targeting unmet medical needs. In July 2025, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) launched JOURNAVX (suzetrigine), a first-in-class, non-opioid treatment for moderate-to-severe acute pain. JOURNAVX, an oral NaV1.8 pain signal inhibitor, was named a 2025 Breakthroughs Innovation Celebration winner by Premier, Inc. It represents the first new class of pain medicine in decades and offers a safer alternative to opioids by directly targeting pain pathways without addiction risks. This launch marks a major advancement in pain management, aligning with public health efforts to reduce opioid use. JOURNAVX is especially relevant for acute pain scenarios such as post-surgical recovery and injury care. A closeup of pills in a pharmacy, representing the high quality medications of the company. Beyond acute pain, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) continues to expand its reach. Its next-gen cystic fibrosis therapy, ALYFTREK, received approval from the European Commission in July 2025, strengthening its global leadership in this area. The company is also advancing gene-editing therapies like CASGEVY for sickle cell and beta thalassemia, and is developing treatments for kidney disease, type 1 diabetes, and rare genetic disorders. While we acknowledge the potential of GOOGL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.

Elevance Health, Inc. (ELV) Downgrades 2025 Earnings Amid Rising Medical Costs
Elevance Health, Inc. (ELV) Downgrades 2025 Earnings Amid Rising Medical Costs

Yahoo

time4 minutes ago

  • Yahoo

Elevance Health, Inc. (ELV) Downgrades 2025 Earnings Amid Rising Medical Costs

We recently compiled a list of Elevance Health, Inc. stands third on our list among the most undervalued healthcare stocks. Elevance Health, Inc. (NYSE:ELV) is a major U.S. healthcare company, known for its insurance brands Anthem and WellPoint, and its growing Carelon health services arm. It serves around 45.6 million medical plan members and is recognized for integrating technology and value-based care to improve healthcare delivery. The company is facing increased healthcare utilization and rising medical costs, especially in the ACA and Medicaid segments. This has led to a downgrade in full-year 2025 earnings. A 'market-wide morbidity shift' is evident, with new ACA enrollees using emergency services at nearly double the rate of commercial members, and Medicaid patients showing higher acuity due to redeterminations. Amid these challenges, some investors see Elevance Health, Inc. (NYSE:ELV) as one of the most undervalued stocks in the healthcare sector, given its long-term positioning and strategic adjustments. The company expects a surge in elective procedures by Q4 2025 as members act ahead of expiring tax credits in 2026 that could raise their out-of-pocket costs. To address these pressures, the business is ramping up AI-driven tools for risk detection, care coordination, and operational efficiency. It's also expanding value-based care contracts, particularly in behavioral health and oncology, with over one-third of benefit expenses tied to risk-sharing models. The company is adjusting pricing strategies for ACA plans and advocating for Medicaid access amid potential regulatory changes. A healthcare professional discussing a treatment plan with a patient in an outpatient clinic. Though total membership fell by 212,000 in Q2 due to Medicaid attrition, the Medicare Advantage segment continues to grow. Elevance Health, Inc. (NYSE:ELV) is prioritizing long-term financial stability over aggressive member growth as it navigates rising costs, shifting regulations, and post-pandemic care patterns. While we acknowledge the potential of GOOGL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

WSJ: Kennedy expected to dismiss expert panel on preventive care
WSJ: Kennedy expected to dismiss expert panel on preventive care

CNN

timean hour ago

  • CNN

WSJ: Kennedy expected to dismiss expert panel on preventive care

US Health and Human Services Secretary Robert F. Kennedy Jr. plans to remove the expert advisers who make up a federal panel on preventive health care, the Wall Street Journal reported Friday. The future of the US Preventive Services Task Force has been in doubt since HHS called off this month's meeting of the nonpolitical advisory group. 'No final decision has been made on how the USPSTF can better support HHS' mandate to Make America Healthy Again,' HHS spokesperson Andrew Nixon told CNN on Friday. The 16-member task force was established in 1984 and provides recommendations about preventive services, such as screenings for cancer and various disorders and counseling, that help make Americans aware of illnesses and conditions earlier, when they can be easier and less expensive to treat. The Affordable Care Act mandates that those services are provided without charge to patients. Kennedy's control over the task force was recently solidified by the US Supreme Court. Last month, in a case challenging a popular provision of the Affordable Care Act, the justices upheld the constitutionality of the task force, which recommends preventive health care services that insurers must cover at no cost. Both the Biden and Trump administrations argued that the task force was properly set up — and therefore, its recommendations should be upheld — because the Health and Human Services secretary was able to name and fire its members. Since taking over at HHS, Kennedy has pushed to reshape the health agencies and expunge them of what he has called longtime health-care industry influence on policies. Last month, he dismissed the 17-member vaccine advisory committee for the US Centers for Disease Control and Prevention and, two days later, named eight new picks. Several of the new members of the Advisory Committee on Immunization Practices have questioned vaccine safety; two have testified in court against vaccine manufacturers.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store